Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04254731
Other study ID # 2012/793 REK
Secondary ID
Status Active, not recruiting
Phase Phase 4
First received
Last updated
Start date May 7, 2015
Est. completion date July 30, 2024

Study information

Verified date April 2024
Source Oslo University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Effects of switching from racemic methadone to R-methadone on serum methadone concentrations and QTc intervals


Description:

Racemic methadone may prolong the QTc interval, which is associated with fatal arrhythmias. In vitro studies have shown that R-methadone has less inhibitory effect than S-methadone on the voltage-gated potassium channel current, and is thus thought to have less effect on the QTc interval. The investigators hypothesized that switching from racemic to R-methadone would reduce the methadone serum concentration and also its effect on the QTc interval.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 10
Est. completion date July 30, 2024
Est. primary completion date June 27, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - Stabilized on daily methadone dose - Not using other drugs of abuse - QTc-time recorded automatically, patient inclusion if QTc interval was greater or equal to 450 ms - Older than 18 years - Can sign and understand a written Consent Exclusion Criteria: - Can not cooperate regarding observed daily drug intake - Serious psychiatric disease - Untreated serious somatic disease - Pregnancy

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Same individuals treated with racemic methadone and switched to levomethadone (R-methadone)


Locations

Country Name City State
Norway Department of Pharmacology , Oslo University Hospital Oslo
Norway Department of Pharmacology and Department of Substance Use Disorder, Oslo University Hospital Oslo
Norway Department of Substance Use Disorder, Oslo University Hospital Oslo

Sponsors (1)

Lead Sponsor Collaborator
Oslo University Hospital

Country where clinical trial is conducted

Norway, 

References & Publications (1)

Havig SM, Berg-Pedersen RM, Krabseth HM, Muller LD, Haugaa K, Zare HK, Gjesdal K, Krajci P, Opdal MS. Effect on QTc interval by switching from methadone to equipotent R-methadone dose in methadone maintenance treatment patients. Basic Clin Pharmacol Toxicol. 2024 Apr;134(4):519-530. doi: 10.1111/bcpt.13982. Epub 2024 Feb 3. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Effects of switching from racemic methadone to R-methadone on serum methadone concentrations. Ten patients stabilized on racemic methadone dose were switched to R-methadone and effects on serum methadone concentrations were studied. Methadone concentrations (nmol/L) were measured by validated high pressure liquid chromatography coupled to mass spectrometry detection (LC-MSMS). Time frame of each patient form inclusion to end study was 35-40 days.
Primary Effects of switching from racemic methadone to R-methadone on QTc interval In ten patients QTc intervals were recorded on racemic methadone treatment at Cmin and Cmax of methadone drug concentrations and likewise after the shift to R-methadone. QT intervals (ms) on ECG were recorded automatically and read manually by experienced cardiologists. Time frame of each patient form inclusion to end study was 35-40 days.
Primary Effects of switching from racemic methadone to R-methadone on opioid withdrawal symptoms (OWS) Ten patients: each patients had OWS recorded on racemic and R-methadone treatment using OWS. Time frame of each patient form inclusion to end study was 35-40 days.
Primary Effects of switching from racemic methadone to R-methadone, stability of serum electrolytes (Ca, Mg, K) in patients Ten patients: samples for serum electrolytes were collected before and after switch to R-methadone. Measured by routine analysis at Cobas 8000 (unit mmol/L) Time frame of each patient form inclusion to end study was 35-40 days.
See also
  Status Clinical Trial Phase
Completed NCT04235894 - An Observer Rating Scale of Facial Expression Can Predict Dreaming in Propofol Anesthesia
Completed NCT04166890 - Comparison of the Efficacy and Safety of Two Homologous Active Principles for Local Dental Anesthesia Phase 4
Completed NCT03265613 - Safety and Efficacy of Expanded Allogeneic AD-MSCs in Patients With Moderate to Severe Psoriasis Phase 1/Phase 2
Recruiting NCT04037774 - Comparision of Different Doses of Dexmedetomidine With Low Dose Bupivacaine in Selective Spinal Anesthesia. Phase 4
Recruiting NCT05113420 - The Efficacy and Safety of Different Phlebotonic Drugs in Children With Venous Malformations
Completed NCT03801629 - Neuroimmune Effects of Opioid Administration Phase 1
Completed NCT04052776 - Acute Effects of Pharmacological Neuromodulation on Leg Motor Activity in Patients With SCI Treated With EES Phase 1
Completed NCT04037085 - Ketamine to Improve Recovery After Cesarean Delivery - Part 1 Phase 2
Completed NCT05050071 - Evaluation of Antibacterial Effect of Allium Sativum, Calcium Hydroxide and Their Combination in Infected Mature Teeth Phase 2/Phase 3
Completed NCT03305666 - Trial of Injected Liposomal Bupivacaine vs Bupivacaine Infusion After Surgical Stabilization of Rib Fractures Phase 4
Completed NCT06238154 - Flurbiprofen Tablet vs Spray In Oral Soft Tissue Wounds Phase 4
Not yet recruiting NCT04392427 - New Antiviral Drugs for Treatment of COVID-19 Phase 3
Recruiting NCT05300152 - Pulpotomy Medications in Primary Teeth N/A
Recruiting NCT04594889 - Comparison of Sirolimus vs Paclitaxel Drug Eluting Balloon for Below-the-knee Angioplasty in Critical Limb Ischemia N/A
Not yet recruiting NCT05018936 - Efficacy and Safety of Hetrombopag in Non-severe Aplastic Anemia Phase 2/Phase 3
Completed NCT04245774 - Comparing the Effects of Levobupivacaine and Bupivacaine in Saddle Spinal Anesthesia Phase 4
Completed NCT04449536 - Cysteine-lowering Treatment With Mesna Phase 1
Recruiting NCT05975255 - Dose Finding Study for Remimazolam in Children Phase 2
Completed NCT03635684 - Evaluation of Efficacy and Safety of Subcutaneous Acetaminophen Phase 2
Active, not recruiting NCT04387201 - GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic Response Phase 4